Phase I Dose Escalation Trial to Determine the Maximum Tolerated Dose of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients With a First, Second or Third Platinum Sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer.
Phase of Trial: Phase I
Latest Information Update: 19 May 2016
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 05 Jan 2016 Planned End Date changed from 1 Oct 2015 to 1 Mar 2016 as reported by CinicalTrials.gov
- 12 Aug 2015 Planned End Date changed from 1 May 2015 to 1 Oct 2015 as reported by CinicalTrials.gov